Clinical trial
A Multicenter, Randomized, Double-Blind, Crossover, Phase 2 Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
NCT05412979 is registered in ClinicalTrials.gov with Sention Therapeutics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Crossover, Phase 2 Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
- Lead sponsor
- Sention Therapeutics, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 29, 2022
- Completion date
- October 4, 2023
- Enrollment
- 490 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.